Philippe Galtie, Tiffany & Co. (TIF)’s insider Sold 1,648 Shares; Iguana Healthcare Management Trimmed Its Dermira (DERM) Stake

Based on an average price per share of $109.5, Philippe Galtie, the Tiffany & Co’s Senior Vice President sold 1,648 shares of Tiffany & Co worth approx. $180,426 U.S Dollars. In the last 30 days, he also sold 26,431 shares with a total value of about $2,900,060 USD. This deal was reported on January 29, 2018 and is already filed with the DC-based SEC. The legal Form 4 is ready for use to the public here. And, It’s sure Philippe’s stocks unloading isn’t going to stay unnoticed as he today is possessing 3,539 shares – ( 0.00% of Tiffany & Co’s Market Cap ).

Iguana Healthcare Management Llc decreased Dermira Inc (DERM) stake by 10.71% reported in 2017Q3 SEC filing. Iguana Healthcare Management Llc sold 15,000 shares as Dermira Inc (DERM)’s stock declined 17.23%. The Iguana Healthcare Management Llc holds 125,000 shares with $3.38M value, down from 140,000 last quarter. Dermira Inc now has $1.26B valuation. The stock decreased 2.33% or $0.72 during the last trading session, reaching $30.21. About 724,602 shares traded or 20.23% up from the average. Dermira, Inc. (NASDAQ:DERM) has declined 7.44% since January 30, 2017 and is downtrending. It has underperformed by 24.14% the S&P500.

Analysts await Tiffany & Co. (NYSE:TIF) to report earnings on March, 16. They expect $1.52 earnings per share, up 4.83% or $0.07 from last year’s $1.45 per share. TIF’s profit will be $188.89 million for 17.98 P/E if the $1.52 EPS becomes a reality. After $0.80 actual earnings per share reported by Tiffany & Co. for the previous quarter, Wall Street now forecasts 90.00% EPS growth.

Among 26 analysts covering Tiffany & Co. (NYSE:TIF), 14 have Buy rating, 0 Sell and 12 Hold. Therefore 54% are positive. Tiffany & Co. has $125.0 highest and $66 lowest target. $97.92’s average target is -10.41% below currents $109.3 stock price. Tiffany & Co. had 84 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Cowen & Co on Friday, November 11. The firm has “Hold” rating by Goldman Sachs given on Friday, September 22. The rating was maintained by RBC Capital Markets on Thursday, July 6 with “Hold”. On Wednesday, April 5 the stock rating was maintained by Jefferies with “Buy”. As per Tuesday, April 11, the company rating was maintained by Cowen & Co. Telsey Advisory Group maintained Tiffany & Co. (NYSE:TIF) on Wednesday, November 30 with “Outperform” rating. Mizuho maintained it with “Buy” rating and $82 target in Friday, August 26 report. The rating was maintained by Needham on Friday, August 25 with “Hold”. The rating was upgraded by Goldman Sachs on Friday, May 12 to “Buy”. As per Thursday, January 21, the company rating was maintained by RBC Capital Markets.

Tiffany & Co., through its subsidiaries, designs, makes, and retails jewelry and other items worldwide. The company has market cap of $13.58 billion. The Company’s jewelry products include fine and solitaire jewelry; engagement rings and wedding bands; and non-gemstone, sterling silver, and gold jewelry. It has a 29.37 P/E ratio. The firm also sells timepieces, leather goods, sterling silverware, china, crystal, stationery, fragrances, and accessories.

The stock decreased 0.37% or $0.41 during the last trading session, reaching $109.3. About 613,521 shares traded. Tiffany & Co. (NYSE:TIF) has risen 46.84% since January 30, 2017 and is uptrending. It has outperformed by 30.14% the S&P500.

Since August 1, 2017, it had 0 buys, and 11 selling transactions for $1.49 million activity. Another trade for 600 shares valued at $16,194 was made by Cohen David E on Monday, October 2. On Tuesday, January 2 BAUER EUGENE A sold $81,210 worth of Dermira, Inc. (NASDAQ:DERM) or 3,000 shares. Another trade for 18,458 shares valued at $499,354 was sold by Griffith Christopher M.. 500 shares valued at $13,791 were sold by WIGGANS THOMAS G on Tuesday, August 1.

Among 9 analysts covering Dermira Inc (NASDAQ:DERM), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. Dermira Inc has $48 highest and $33 lowest target. $42.88’s average target is 41.94% above currents $30.21 stock price. Dermira Inc had 21 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Dermira, Inc. (NASDAQ:DERM) earned “Buy” rating by Cantor Fitzgerald on Monday, November 6. The firm earned “Buy” rating on Wednesday, January 17 by Leerink Swann. The firm earned “Buy” rating on Wednesday, May 11 by Needham. The company was maintained on Tuesday, July 25 by Cantor Fitzgerald. The firm earned “Outperform” rating on Wednesday, August 19 by Cowen & Co. Guggenheim initiated the stock with “Buy” rating in Tuesday, December 5 report. The company was maintained on Friday, September 15 by Needham. The firm earned “Buy” rating on Thursday, September 7 by Mizuho. Needham maintained Dermira, Inc. (NASDAQ:DERM) rating on Tuesday, November 7. Needham has “Buy” rating and $43.0 target. Mizuho maintained Dermira, Inc. (NASDAQ:DERM) on Tuesday, December 12 with “Buy” rating.

Iguana Healthcare Management Llc increased Cymabay Therapeutics Inc (NASDAQ:CBAY) stake by 145,000 shares to 250,000 valued at $2.02 million in 2017Q3. It also upped Intersect Ent Inc (NASDAQ:XENT) stake by 20,000 shares and now owns 90,000 shares. Zimmer Biomet Hldgs Inc (ZMH) was raised too.

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 27. They expect $-1.31 earnings per share, down 523.81% or $1.10 from last year’s $-0.21 per share. After $-1.21 actual earnings per share reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 8.26% negative EPS growth.

Investors sentiment increased to 2.03 in 2017 Q3. Its up 0.64, from 1.39 in 2017Q2. It increased, as 15 investors sold DERM shares while 21 reduced holdings. 22 funds opened positions while 51 raised stakes. 41.09 million shares or 3.89% more from 39.55 million shares in 2017Q2 were reported. Credit Suisse Ag has invested 0% in Dermira, Inc. (NASDAQ:DERM). Citadel Advsr Limited Liability Corp invested in 493,798 shares. Numeric Invsts Limited Liability accumulated 0.01% or 42,543 shares. Nea Co Limited Liability Com reported 3.51 million shares. C World Wide A S has invested 0.06% in Dermira, Inc. (NASDAQ:DERM). Guggenheim Cap Limited Liability Company owns 252,103 shares for 0.02% of their portfolio. Invesco Ltd has 0.01% invested in Dermira, Inc. (NASDAQ:DERM) for 526,287 shares. Amer Century Companies invested in 0% or 43,546 shares. State Board Of Administration Of Florida Retirement Systems owns 0% invested in Dermira, Inc. (NASDAQ:DERM) for 13,433 shares. Voya Investment Mgmt Ltd Liability has invested 0.09% in Dermira, Inc. (NASDAQ:DERM). California State Teachers Retirement Systems holds 0% in Dermira, Inc. (NASDAQ:DERM) or 60,958 shares. Iguana Health Mngmt Lc holds 1.88% or 125,000 shares in its portfolio. Timessquare Mngmt Limited Liability Company reported 2.28M shares stake. Goldman Sachs Grp Incorporated holds 0% in Dermira, Inc. (NASDAQ:DERM) or 174,210 shares. Moreover, Clough Prns Ltd Partnership has 0.39% invested in Dermira, Inc. (NASDAQ:DERM).